Hepatitis B related cirrhosis
Conditions
Interventions
Gold Standard:Pathological diagnosis
Index test:prediction 
model 
for 
no 
reversal 
or 
unstable 
compensation 
of 
cirrhosis
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The design of this study belongs to the retrospective and ambispective cohort study. This study included two groups of patients: Patients in Group I come from the retrospective cohort and in Group II come from the ambispective cohort. The ambispective cohort will be created by this study. 1. Inclusion criteria for patients in Group I: HBsAg positive chronic hepatitis; pathological diagnosis of liver cirrhosis had been made after more than 1 year of non antiviral therapy, and antiviral therapy had begun within 8 weeks before and after liver biopsy (antiviral starting point); pathological diagnosis had been made again after 2 to 3 years of antiviral therapy (antiviral ending point); complete outpatient and inpatient records, and complete routine laboratory and ultrasonic data at antiviral starting point and ending point (within 4 weeks before and after liver biopsy) had been left; The matching serum had been taken at antiviral starting point and ending point (within 4 weeks before and after liver biopsy). 2. Inclusion criteria for patients in Group II: HBsAg positive chronic hepatitis; pathological diagnosis of liver cirrhosis was made after more than 1 year of non antiviral therapy, and antiviral therapy began within 8 weeks before and after liver biopsy (antiviral starting point); pathological diagnosis will be made again after 2 to 3 years of antiviral therapy (antiviral ending point); complete outpatient and inpatient records, and complete routine laboratory and ultrasonic data at antiviral starting point (within 4 weeks before and after liver biopsy) was left; The matching serum was taken at antiviral starting point (within 4 weeks before and after liver biopsy).
Exclusion criteria
Exclusion criteria: 1. Combined with other hepatitis, schistosomiasis liver disease, drug-induced liver injury, alcoholic liver disease, hereditary liver disease, endocrine and metabolic diseases, autoimmune diseases, blood system diseases, chronic intestinal diseases, uncontrolled heart/lung diseases and kidney diseases; 2. severe infection of any site except spontaneous bacterial peritonitis (Fever more than 3 days, inflammatory and anti-inflammatory symptoms more than 3 weeks) occurred within 4 weeks before and after liver biopsy; 3. serum HBV DNA > 1000 IU/mL after six months of antiviral therapy; 4. poor adherence or combined with anti-fibrotic, hepato-protective, and inflammatory drugs; not suitable for liver biopsy the investigators concluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SEN, SPE, ACC, AUC of ROC, PPV, NPV; | — |
Countries
China
Contacts
Public ContactZhan-qing Zhang
Shanghai Public Health Clinical Center
Outcome results
None listed